Absolute bioavailability of moxifloxacin

被引:43
作者
Ballow, C
Lettieri, J
Agarwal, V
Liu, P
Stass, H
Sullivan, JT
机构
[1] Millard Fillmore Hosp, Clin Pharmacokinet Lab, Buffalo, NY 14209 USA
[2] SUNY Buffalo, Sch Pharm, Buffalo, NY 14260 USA
关键词
BAY; 12-8039; moxifloxacin; pharmacokinetics; bioavailability;
D O I
10.1016/S0149-2918(00)88306-X
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Moxifloxacin (BAY 12-8039) is an investigational 8-methoxy-fluoroquinolone with broad-spectrum gram-positive and gram-negative activity. To determine the absolute bioavailability of moxifloxacin, this open-label, randomized, crossover study compared the pharmacokinetic characteristics of a single 100-mg dose administered either orally or intravenously as a 60-minute infusion in 10 healthy male volunteers (mean age [+/- SD], 29.3 +/- 7.1 years; mean weight [+/- SD], 77.7 +/- 8.7 kg). Geometric mean values for oral/IV moxifloxacin were as follows: peak serum concentration, 1.15/1.34 mg/L, and area under the concentration-time curve over 48 hours, 9.86/10.89 mg.h/L. The geometric mean absolute bioavailability of oral moxifloxacin was 91.8%. Mean renal clearance was approximately 2.3 L/h after administration of both the single oral and IV formulations, which suggests lack of active tubular secretion of moxifloxacin. Both the oral and IV formulations were well tolerated, with 5 repented possible or probable drug-related adverse events; they included headache, nausea, and localized urticaria. In summary, a single oral dose of moxifloxacin was extensively absorbed in healthy young men. Further studies are necessary in actual patients to confirm the viability of IV to oral conversion at the same dose of moxifloxacin.
引用
收藏
页码:513 / 522
页数:10
相关论文
共 22 条
[1]   In vitro activity of BAY 12-8039, a novel 8-methoxyquinolone, compared to activities of six fluoroquinolones against and Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [J].
Brueggemann, AB ;
Kugler, KC ;
Doern, GV .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (07) :1594-1597
[2]   Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses [J].
Chien, SC ;
Rogge, MC ;
Gisclon, LG ;
Curtin, C ;
Wong, F ;
Natarajan, J ;
Williams, RR ;
Fowler, CL ;
Cheung, WK ;
Chow, AT .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2256-2260
[3]  
FELMINGHAM D, 1996, 36 INT C ANT AG CHEM
[4]  
FERGUSSON J, 1998, 8 INT C INF DIS MAY
[5]  
GEORGOPOULOUS A, 1996, 36 INT C ANT AG CHEM
[6]  
Gibaldi M. P., 1982, PHARMACOKINETICS
[7]  
KUBITZA D, 1996, 36 INT C ANT AG CHEM
[8]   PHARMACOKINETIC PROFILES OF CIPROFLOXACIN AFTER SINGLE INTRAVENOUS AND ORAL DOSES [J].
LETTIERI, JT ;
ROGGE, MC ;
KAISER, L ;
ECHOLS, RM ;
HELLER, AH .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) :993-996
[9]  
NAKASHIMA M, 1995, JPN J CHEMOTHER S1, V43, P155
[10]  
RENAUDIN H, 1996, 36 INT C ANT AG CHEM